Last Modified, 1 April 03
MOSTAFA Z. BADR, Ph.D.
Associate Professor of Pharmacology
badrm@umkc.edu
Academic Background:
B.S. (Pharmacy) Cairo University, Egypt, 1973
M.S. (Pharmaceutical Chemistry), Cairo University, Egypt, 1978
Ph.D. (Pharmacology/Toxicology), University of Louisville, 1983
Postdoctoral Fellow, University of North Carolina-Chapel Hill, 1984-1987
Research Interests:
The major role of my research activities is to investigate molecular and biochemical mechanisms whereby various therapeutic agents and industrial chemicals cause hepatic peroxisome and cell proliferation, as well as modulate the body immune response. Roles of aging, metabolic diseases (diabetes) and nutrients in these processes are characterized using biochemical and molecular biological techniques.
Representative peer-reviewed publications:
· Taylor, B., Dadia, N., Yang, C., Krishnan, S. and M Badr (2002). Peroxisome Proliferator-Activated Receptor Agonists Inhibit Inflammatory Edema and Hyperalgesia. Inflammation 26, 121-127.
· Youssef, J and M. Badr (2002) Enhanced hepatotoxicity due to agonists of peroxisome proliferator-activated receptors in senescent rats. Role of peroxisome proliferation, cell proliferation and apoptosis The ScientificWorldJOURNAL 2, 1491-1500.
· Badawi and M. Badr (2002). Chemoprevention of Breast Cancer By Targeting Cyclooxygenase-2 and Peroxisome Proliferator-Activated Receptor gamma. Int. J. Oncology 20, 1109-1122.
· Chao, C., Youssef, J., Rezaiekhaleigh, M., Birnbaum, L., and M. Badr (2002). Senescence-Associated Decline in Hepatic Peroxisomal Enzyme Activities Corresponds with Diminished Levels of Retinoid X Receptor alpha, but not Peroxisome Proliferator-Activated Receptor alpha. Mech. Ageing & Develop. 123, 1471-1478.
· J. Youssef, and M. Badr. (2001). Peroxisome Proliferator-Activated Receptors: From Orphanage to Fame in a Decade. Saudi Pharmaceutical J. 9, 1-13.
· J. Youssef, L. Birnbaum, L. Roberts, L. Swift, J. Morrow and M. Badr (2001). Brain Oxidative Stress, Senescence and Death. Isoprostanes and Neuroprostanes: Novel Markers and New Theories in: Antioxidants and Free Radicals in Health and Disease (J. Marwah and A. Kanthasamy, eds.), Prominent Press.
· J. Youssef and M. Badr (2001). “Peroxisomal alterations in aging and disease”. in: Interorganellar Signaling in Age-Related Disease, (M. Mattson, ed.). Advances in Cell Aging and Gerontology, Vol 7, 1-28, Elsevier Press.
· J. Youssef and M. Badr (1999). Biology of the Senescent Liver Peroxisomes. Role in hepatocellular Aging and Disease. Environ. Health Prespec. 107, 791-797.
· Xu, L. and M. Badr (1999). Enhanced potential for oxidative stress in hyperinsulinemic rats. imbalance between hepatic peroxisomal hydrogen peroxide production and decomposition due to hyperinsulinemia. Horm. Metab. Res. 31, 278-282.
· Udata, C., Mitra, A. and M. Badr (1999). Disposition of cosalane, a novel anti-HIV agent, in isolated perfused rat livers. Drug Metab. Dispos. 27, 947-950.
· J. Youssef and M. Badr (1998). Extraperoxisomal Targets of Peroxisome proliferators, Mitochondrial, Microsomal and Cytosolic Effects. Implications for Health and Disease. Crit. Rev. Toxicol. 28, 1-33.
· M. Soliman, M. Cunningham, J. Morrow, L.J. Roberts II and M. Badr (1997). Evidence against peroxisome proliferation-induced hepatic oxidation damage: levels of esterified isoprostanes in lives of mice fed a diet containing WY-14,643. Biochem. Pharmacol. 53, 1369-1374.
· J. Youssef, W. Song and M. Badr (1997). Mitochondrial, but not peroxisomal, ß-oxidation of fatty acids is conserved in coenzyme A-deficient rat liver. Mol. Cell Biochem. 175, 37-42
Representative Research Grants:
1988-1990 Role of altered lipid metabolism in peroxisomal proliferation, NIH, $71,034.
1992-1994 Are acyl-CoA esters the proximate peroxisome proliferators?, UMRB, $45,000.
1996-1997 Immunotoxicity of peroxisome proliferators, Sarah Morrison Fund, $11,200.
1997-2000 Aging, PPAR and Hepatic Peroxisomes, NIH, $68,000.
2000-2002 Brain Oxidative Stress: A Sign of Aging or a Sign of Eminent Death, NIH, $50,000.